PPIB and non-small cell lung carcinoma: Herein, Sal B treatment markedly reduced glucose uptake, lactate production, enolase activity, cellular ATP production, OCR, and ECAR of NCI-H2030 and NCI-H1650 cells, demonstrating that Sal B weakened the metabolic reprogramming of NSCLC cells.